Opinion|Videos|October 18, 2024
Real-World Considerations for New Therapies
Key Takeaways
- New therapies must show significant clinical improvements, such as enhanced efficacy or reduced side effects, over current standards to be considered for adoption.
- Cost-effectiveness, ease of administration, and alignment with existing protocols are crucial non-clinical factors influencing treatment adoption decisions.
Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What clinical improvements would a new therapy need to demonstrate over the current standard of care to warrant consideration for adoption, and what additional factors influence your decision-making process when evaluating treatment changes?
Advertisement
Related to this article
For as long as practicing oncology pharmacists have been in the field, multiple myeloma carried a standard caveat: treatable, not curable—now that is changing.
Linvoseltamab drives deep, MRD-negative responses in high-risk smoldering multiple myeloma, raising earlier-treatment and payer coverage questions.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Phase 3 CERVINO results show that monthly etentamig significantly improved PFS and response rates compared with investigator-selected therapy in patients with previously treated multiple myeloma.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Armored CAR T-Cell Therapy Produces Durable Complete Response in Pediatric Solid Tumors
2
Expert Q&A: Pharmacists Address Pneumococcal Vaccine Hesitancy and Screening Complexity in Transitions of Care
3
Not So Rare After All: Pharmacists Weigh In on Diagnosing and Managing ATTR-CM
4
Semaglutide Linked to Up to 40% Fewer Asthma Attacks, Real-World Data Show
5